South Korea's Samsung Biologics signs $231 million supply deal with GSK

South Korean contract drugs manufacturer Samsung Biologics Co Ltd said on Friday it had signed a deal worth more than $231 million with GlaxoSmithKline PLC (GSK) to supply biopharmaceutical products over the next eight years.

from Reuters: Technology News https://ift.tt/3cTbMqn